Tumor-associated macrophages in skin: How to treat their heterogeneity and plasticity.
about
Alternatively Activated (M2) Macrophage Phenotype Is Inducible by Endothelin-1 in Cultured Human Macrophages.The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer.Differentiated State of Initiating Tumor Cells Is Key to Distinctive Immune Responses Seen in H-RasG12V-Induced Squamous Tumors.M2-Polarized Macrophages Compose Lupus Vulgaris Arising from a Bacillus Calmette-Guérin Vaccination Site.Sarcoidosis-Lymphoma Syndrome Associated with Folliculotropic Peripheral T Cell Lymphoma Not Otherwise Specified.Successful Treatment of Primary Cutaneous Peripheral T-Cell Lymphoma Presenting Acquired Ichthyosis with Oral Bexarotene Monotherapy.Recurrent Multiple Squamous Cell Carcinomas on the Scalp in a Patient with Juvenile Dermatomyositis.Phase I study of nivolumab combined with IFN-β for patients with advanced melanoma.The axis IL-10/claudin-10 is implicated in the modulation of aggressiveness of melanoma cells by B-1 lymphocytes.Advances in Proteomic Techniques for Cytokine Analysis: Focus on Melanoma Research.Cytotoxic antimelanoma drugs suppress the activation of M2 macrophages.Tumor-Associated Macrophages: Therapeutic Targets for Skin Cancer.Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient.Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study.Intensity-Modulated Radiotherapy Triggers Onset of Bullous Pemphigoid in a Patient with Advanced Melanoma Treated with Nivolumab.The novel immunoglobulin super family receptor SLAMF9 identified in TAM of murine and human melanoma influences pro-inflammatory cytokine secretion and migration
P2860
Q36192785-352D769C-4EE6-4753-AED5-49B448F9BD67Q38654867-3749CB63-27E5-4B3E-A0A4-264B8D553FC2Q38991275-584E743C-0141-479C-A754-217DCA344F5DQ40835334-069457BD-5D60-4B05-B496-48066D9C493DQ42091335-91C033E7-79EE-492C-9685-9674380E398AQ42283591-DFDDE442-04EE-4897-9432-F3F665C6F9C2Q42322606-EA07C5BE-497F-4EB9-9020-C3E28814C76CQ42378520-5D8D069B-C692-44EF-B6C7-4E481FFD2F9BQ47106432-27DC89ED-B124-4242-BA6C-4D715CDACAEBQ47225640-B01C871D-D6B7-4D72-83D9-08690D377BEDQ47916295-8C21B640-0033-42ED-B620-14AEF0AE024DQ49168232-B55E10C5-80D3-41C6-AB3A-4BABD3095F34Q53983385-E964504F-A303-4B18-BE3E-AC3D83C75986Q55004957-A5A1FC83-9EED-45CA-B90C-F6435B209B08Q55100888-E59E34B2-D391-4397-B763-29DC0BDAF27FQ57154469-1EFFAD00-43F8-4B73-BA6E-A48F50B0C668
P2860
Tumor-associated macrophages in skin: How to treat their heterogeneity and plasticity.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Tumor-associated macrophages in skin: How to treat their heterogeneity and plasticity.
@en
type
label
Tumor-associated macrophages in skin: How to treat their heterogeneity and plasticity.
@en
prefLabel
Tumor-associated macrophages in skin: How to treat their heterogeneity and plasticity.
@en
P2093
P1476
Tumor-associated macrophages in skin: How to treat their heterogeneity and plasticity.
@en
P2093
Aya Kakizaki
Sadanori Furudate
Setsuya Aiba
Taku Fujimura
Yumi Kambayashi
P304
P356
10.1016/J.JDERMSCI.2016.05.015
P577
2016-05-25T00:00:00Z